Pharma Pushes Lawmakers to Reward Antibiotic Developers

April 29, 2019
National Journal

Antibiotic resistance has made common illnesses more difficult to treat and threatens to become a deadly killer in the decades to come. But even with this growing threat of “superbugs,” pharmaceutical companies have struggled financially to maintain research and development into new antibiotic treatments.

Public-health experts and drug companies are now calling on Congress to enact policies that would help manufacturers overcome financial hurdles to developing and marketing new antimicrobial products.

A United Nations report released Monday recommended intensifying the support for research and development of new antimicrobials. “Alarming levels of resistance” have been seen in countries of all income levels, and common diseases are “becoming untreatable,” according to the study.

View the full story (site requires registration)